Clinical Practice Session
Controversies in the Management of Kidney Dysfunction in Advanced Liver Disease
November 06, 2025 | 10:30 AM - 12:30 PM
Location: Grand Ballroom C, Convention Center
Session Description
Creatinine has limitations in cirrhosis, in which women and patients with sarcopenia may be vulnerable to inaccuracy/overestimation of kidney function. Hepatorenal syndrome is associated with high mortality, and successful therapy with terlipressin avoids kidney replacement therapy with peritransplant benefit, yet a decline in serum creatinine may result in lower wait-list priority. Following implementation of simultaneous liver-kidney transplant (SLKT) eligibility criteria and safety net policy in 2017, questions remain regarding outcomes among those who experience kidney failure after liver transplantation.
Learning Objective(s)
- List limitations of serum creatinine and the potential role of other kidney biomarkers in evaluating kidney function among liver transplant candidates
- Identify patients with hepatorenal syndrome who may benefit most from undergoing therapy in the context of liver transplantation and discuss how organ allocation policy could facilitate an optimal management strategy
- Discuss the impact of AKI vs. CKD on pre- and post-transplant outcomes, including criteria for SLKT and eligibility for safety net kidney-after-liver transplantation
Learning Pathway(s)
- Kidney Transplantation
- AKI and Critical Care
Moderators
Presentations
- Serum Creatinine: Strengths and Limitations in Liver Disease
10:30 AM - 11:00 AM
- Treatment of Hepatorenal Syndrome: Implications for Liver and Kidney Transplantation
11:00 AM - 11:30 AM
- SLKT and Safety Net Listing: Implications for Nephrology Professionals
11:30 AM - 12:00 PM
- Kidney Replacement Therapy in Cirrhosis: Difficult Discussions
12:00 PM - 12:30 PM